WO2024031949A1 - 纳米酶复合水凝胶滴眼液的制备方法 - Google Patents

纳米酶复合水凝胶滴眼液的制备方法 Download PDF

Info

Publication number
WO2024031949A1
WO2024031949A1 PCT/CN2023/076110 CN2023076110W WO2024031949A1 WO 2024031949 A1 WO2024031949 A1 WO 2024031949A1 CN 2023076110 W CN2023076110 W CN 2023076110W WO 2024031949 A1 WO2024031949 A1 WO 2024031949A1
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
add
solution
eye drops
aqueous solution
Prior art date
Application number
PCT/CN2023/076110
Other languages
English (en)
French (fr)
Inventor
周庆军
史伟云
王红卫
宋方英
Original Assignee
山东第一医科大学附属眼科研究所(山东省眼科研究所、山东第一医科大学附属青岛眼科医院)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 山东第一医科大学附属眼科研究所(山东省眼科研究所、山东第一医科大学附属青岛眼科医院) filed Critical 山东第一医科大学附属眼科研究所(山东省眼科研究所、山东第一医科大学附属青岛眼科医院)
Publication of WO2024031949A1 publication Critical patent/WO2024031949A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention belongs to the field of eye drops and medicines, and specifically relates to a preparation method of nanozyme composite hydrogel eye drops.
  • Bacterial keratitis is an infection caused by bacterial invasion of the cornea. It develops rapidly and can cause corneal ulcers or even perforation in severe cases. It is one of the major blinding eye diseases in developing countries.
  • the most common predisposing factors include: contact lens use, especially at night or long-term wear and inadequate lens disinfection; trauma; ocular surgery, especially corneal surgery; chronic ocular surface disease; systemic disease such as diabetes and/or topical corticosteroids Long-term use of steroids.
  • the most common pathogens causing keratitis include Staphylococcus aureus, Pseudomonas aeruginosa, Streptococcus pneumoniae and Serratia.
  • Pseudomonas aeruginosa keratitis infection is the most serious and difficult to treat. treat.
  • Clinical treatment of Pseudomonas aeruginosa keratitis focuses on lesion removal and frequent administration of topical antibiotics to control the development of corneal ulcers as efficiently and quickly as possible.
  • topical antibiotics also involves certain risks and problems.
  • a review of clinical trials of topical antibiotics for the treatment of bacterial keratitis found that aminoglycoside cephalosporins had an increased relative risk of minor adverse events, such as ocular discomfort or chemical conjunctivitis, compared with fluoroquinolones. Increase.
  • the present invention provides a method for preparing nanozyme composite hydrogel eye drops, which first uses hexahydrate The coordination reaction of cobalt chloride and ammonia and the redox reaction of silver nitrate and tannic acid synthesize a tannic acid-complexed silver-cobalt composite nanoparticle (TCN); use water as the medium to mix TCN and acrylate-modified gelatin Ultrasonicate until uniform, and then irradiate with ultraviolet light to prepare nanozyme composite hydrogel material (TCNH) in one step; then mix it with hydrogen peroxide solution to obtain TCNH eye drops.
  • TCN tannic acid-complexed silver-cobalt composite nanoparticle
  • TCNH nanozyme composite hydrogel material
  • the obtained eye drops show broad-spectrum bactericidal effects on a variety of bacteria and fungi, and have good preventive and therapeutic effects on bacterial and drug-resistant bacterial corneal infections.
  • the preparation method of the nanozyme composite hydrogel eye drops provided by the invention includes the following steps:
  • the preparation method of nanozyme composite hydrogel eye drops includes the following steps:
  • step (2) Add silver acetate to the ammonia solution and dissolve it completely. Slowly add the solution dropwise to step (1). After stirring for a period of time, add the tannic acid solution dropwise. Continue stirring to precipitate; centrifuge, clean and dry. Precipitate and store at 350-450°C Calculate for 1-4 hours to obtain tannic acid-combined silver-cobalt composite nanoparticles;
  • the concentration of the cobalt chloride aqueous solution is 20-30mmol/L.
  • ammonia water is an aqueous solution containing 20% to 28% ammonia.
  • step (1) ammonia water is added dropwise to the cobalt chloride aqueous solution, the temperature is gradually raised to 55-65°C, and stirring is continued for 12-18 minutes; the cobalt chloride aqueous solution is then added dropwise to continue the reaction for 1-4 hours.
  • step (2) the silver ammonia solution was slowly added dropwise and stirred for 15 min.
  • the tannic acid solution was slowly added dropwise and stirred at room temperature for 16 h.
  • step (2) wash with water and ethanol in sequence, dry at 60°C for 4 hours, and then calcined at 400°C for 3 hours.
  • the acrylate-modified gelatin is methacrylate-modified gelatin.
  • the mass concentration of acrylate modified gelatin in the mixture of step (3) is 2.0%-6.0%.
  • the irradiation time under ultraviolet light in step (3) is 12-18 minutes.
  • the mass ratio of acrylate-modified gelatin and tannic acid-combined silver-cobalt composite nanoparticles is 8-12:1.
  • the invention has beneficial effects: the preparation method is simple to operate and the preparation time is short; the obtained eye drops show a broad-spectrum bactericidal effect on a variety of bacteria and fungi, and have good preventive and therapeutic effects on bacterial and drug-resistant corneal infections.
  • Figure 1 is a scanning electron microscope photo of the TCN nanozyme prepared in the Example; the nanozyme has a spherical stacking morphology.
  • Figure 2 is a scanning electron microscope photograph of the TCNH eye drops prepared in the Example; the morphology of the eye drops is a typical hydrogel with large pores of tens of microns.
  • Figure 3 is an optical photograph of the TCNH eye drops prepared in the Example; the nanozyme is evenly dispersed in the eye drops.
  • Figure 4 shows the in vitro bacteriostatic test of the TCNH eye drops prepared in the Example - plate test.
  • Figure 5 shows the in vitro antibacterial experiment of the TCNH eye drops prepared in the Example - the number of viable bacteria stained green in the control group and the H 2 O 2 group.
  • Figure 6 shows the in vitro antibacterial experiment of the TCNH eye drops prepared in the Example - the bacterial morphology of the control group and the H 2 O 2 group under a scanning electron microscope.
  • Figure 7 shows the in vivo antibacterial experiment (Pseudomonas aeruginosa) of the TCNH eye drops prepared in the Example - control group and H 2 O 2 group Obvious corneal infection.
  • Figure 8 shows the in vivo antibacterial experiment of the TCNH eye drops prepared in the Example (Pseudomonas aeruginosa drug-resistant bacteria).
  • step (3) Add 1.0 mL of 25% ammonia solution dropwise into the centrifuge tube in step (2), gradually raise the temperature to 60°C, and continue stirring for 15 minutes;
  • step (6) Slowly add the solution in step (5) dropwise to the solution in step (4), and continue stirring for 15 minutes;
  • step (8) Slowly add the solution in step (7) dropwise to the solution in step (6), and stir at room temperature for 16 hours;
  • step (8) Centrifuge the solution in step (8), wash with water and ethanol, dry at 60°C for 4 hours, and then calcine at 400°C for 3 hours to obtain TCN;
  • step (12) Place the centrifuge tube in step (12) under UV light for 15 minutes.
  • Benzoin dimethyl ether is used as the photoinitiator.
  • the acrylate-modified gelatin has a low concentration, so slight cross-linking occurs, forming a gel-like aqueous solution, TCN Evenly dispersed in gel aqueous solution;
  • step (14) Add hydrogen peroxide solution to the centrifuge tube in step (13) and sonicate at room temperature until uniform to obtain TCNH eye drops.
  • the TCNH eye drops prepared in the obtained examples were applied to the evaluation of Escherichia coli, Pseudomonas aeruginosa, drug-resistant Pseudomonas aeruginosa and Candida albicans in vitro and the evaluation of Pseudomonas aeruginosa and drug-resistant Pseudomonas aeruginosa in vivo Experiments on the prevention and treatment of corneal infection.
  • Figures 4 to 6 show the results of in vitro antibacterial experiments of TCNH eye drops. Antibacterial effect of Pseudomonas aeruginosa, drug-resistant Pseudomonas aeruginosa, Escherichia coli and Candida albicans: As shown in Figure 4, the bacteria in the control group and H 2 O 2 group covered the plate, TCNH and No bacterial colonies were formed on the TCNH+H 2 O 2 group plates. As shown in Figure 5, the control group and H 2 O 2 group had more live bacteria dyed green, and fewer dead bacteria dyed red. The number of bacteria in the TCNH and TCNH+H 2 O 2 groups was significantly reduced. There are only a few scattered ones in the field of vision.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

一种纳米酶复合水凝胶滴眼液的制备方法，利用六水氯化钴与氨水的配位反应以及硝酸银与单宁酸的氧化还原反应合成一种单宁酸配合的银钴复合纳米粒子；将银钴复合纳米粒子和丙烯酸酯修饰明胶混合并超声溶解，然后通过紫外光照射制备出纳米酶复合水凝胶滴眼液。制备方法操作简便且制备时间短，所得滴眼液对多种细菌和真菌具有广谱杀菌的效果，对细菌性和耐药菌角膜感染具有预防治疗效果。

Description

纳米酶复合水凝胶滴眼液的制备方法 技术领域
本发明属于滴眼液药物领域，具体涉及纳米酶复合水凝胶滴眼液的制备方法。
背景技术
细菌性角膜炎是由于细菌侵袭角膜引发的感染，发病迅速，严重者会引发角膜溃疡甚至穿孔，是发展中国家主要致盲性眼病之一。最常见的诱发因素包括：使用隐形眼镜，特别是夜间或长期佩戴隐形眼镜以及镜片消毒不充分；外伤；眼部手术特别是角膜手术；慢性眼表疾病；全身性疾病如糖尿病和/或外用皮质类固醇的长期使用。在常见细菌性病原体中，引起角膜炎最常见的病原体包括金黄色葡萄球菌、铜绿假单胞菌、肺炎链球菌和沙雷氏菌，其中以铜绿假单胞菌性角膜炎感染发病最为严重并且难以治疗。临床上对铜绿假单胞菌性角膜炎的治疗以病灶清除和局部抗生素的频繁用药为主，以尽可能高效快速的控制住角膜溃疡发展。但是，抗生素的使用亦存在一定程度的风险和问题。一项对外用抗生素治疗细菌性角膜炎的临床实验回顾分析显示，与氟喹诺酮类药物相比，氨基糖苷类头孢菌素类药物引起眼部不适或化学结膜炎等轻微不良事件的相对风险有所增加。对眼表分离铜绿假单胞菌耐药性回顾分析表明，铜绿假单胞菌对环丙沙星(9％)、庆大霉素(22％)和头孢他啶(13％)等常见眼部抗生素的平均耐药率虽然相对较低，但对于其耐药性有逐年升高的趋势。所以，对于研发针对铜绿假单胞菌性角膜炎治疗的新型抗菌药物仍是紧迫且必需的。
发明内容
针对引起角膜炎的病原体对常见眼部抗生素的耐药性呈现增加趋势，亟需新型抗菌药物的上述问题，本发明提供一种纳米酶复合水凝胶滴眼液的制备方法，先利用六水氯化钴与氨水的配位反应以及硝酸银与单宁酸的氧化还原反应合成一种单宁酸配合的银钴复合纳米粒子(TCN)；以水为媒介，将TCN和丙烯酸酯修饰明胶混合并超声至均匀，然后通过紫外光照射一步制备出纳米酶复合水凝胶材料(TCNH)；进而与过氧化氢溶液混合均匀即得TCNH滴眼液。所得滴眼液对多种细菌及真菌显示了广谱杀菌的效果，并对细菌性和耐药菌角膜感染具有良好的预防治疗效果。
本发明提供的纳米酶复合水凝胶滴眼液的制备方法包括以下步骤：
纳米酶复合水凝胶滴眼液的制备方法，包括以下步骤：
(1)向氯化钴水溶液中滴加少量氨水，反应一段时间，再滴加氯化钴水溶液继续反应；
(2)将醋酸银加入到氨水溶液中并完全溶解，将该溶液缓慢滴加到步骤(1)中，搅拌一段时间后滴加单宁酸溶液，继续搅拌，析出沉淀；离心、清洗、干燥沉淀并于350-450℃下 煅烧1-4h，即得单宁酸配合的银钴复合纳米粒子；
(3)将制得的单宁酸配合的银钴复合纳米粒子加入到5wt％-7.5wt％的丙烯酸酯修饰明胶的水溶液中，并加入安息香二甲醚乙醇溶液作为引发剂，超声至均匀，然后将上述混合物置于紫外光下照射，形成凝胶状溶液，再加入过氧化氢溶液并在室温下超声至均匀，即得纳米酶复合水凝胶滴眼液。
进一步的，所述氯化钴水溶液的浓度为20-30mmol/L。
进一步的，所述氨水为含氨20～28％的水溶液。
进一步的，所述步骤(1)向氯化钴水溶液中滴加氨水，逐步升温至55-65℃，并继续搅拌12-18min；再滴加氯化钴水溶液继续反应1-4h。
进一步的，所述步骤(2)缓慢滴加银氨溶液，搅拌15min，缓慢滴加单宁酸溶液，室温搅拌16h。
进一步的，所述步骤(2)依次用水和乙醇清洗，60℃干燥4h，然后置于400℃下煅烧3h。
进一步的，所述丙烯酸酯修饰明胶为甲基丙烯酸酯化明胶。
进一步的，所述步骤(3)混合物中，丙烯酸酯修饰明胶的质量浓度为2.0％-6.0％。
进一步的，所述步骤(3)紫外光下照射时间为12-18min。
进一步的，所述步骤(3)混合物中，丙烯酸酯修饰明胶与单宁酸配合的银钴复合纳米粒子的质量比为8-12：1。
本发明的有益效果：制备方法操作简便且制备时间短；所得滴眼液对多种细菌和真菌显示了广谱杀菌的效果，并对细菌性和耐药菌角膜感染具有良好的预防治疗效果。
附图说明
图1为实施例制备的TCN纳米酶的扫描电镜照片；纳米酶为球状堆积形貌。
图2为实施例制备的TCNH滴眼液的扫描电镜照片；滴眼液形貌为典型的水凝胶数十微米大孔的形貌。
图3为实施例制备的TCNH滴眼液的光学照片；纳米酶均匀分散在滴眼液中。
图4为实施例制备的TCNH滴眼液的体外抑菌实验-平板实验。
图5为实施例制备的TCNH滴眼液的体外抑菌实验-对照组和H2O2组被染成绿色的活细菌数数量。
图6为实施例制备的TCNH滴眼液的体外抑菌实验-扫描电镜下对照组和H2O2组细菌形态。
图7为实施例制备的TCNH滴眼液的体内抑菌实验(铜绿假单胞菌)-对照组和H2O2组 角膜明显感染情况。
图8为实施例制备的TCNH滴眼液的体内抑菌实验(铜绿假单胞菌耐药菌)。
具体实施方式
下面结合具体实施例对本发明做进一步详细说明。
实施例
(1)向离心管中加入238.0mg六水氯化钴；
(2)向步骤(1)的离心管中加入50.0mL水并超声至完全溶解；
(3)向步骤(2)的离心管中逐滴加入1.0mL 25％氨水溶液，逐步升温至60℃，并继续搅拌15min；
(4)向步骤(3)的离心管中加入20.0mL25mmol/L六水氯化钴溶液，继续反应3h；
(5)250.3mg醋酸银加入到10mL 25％氨水溶液中，超声至完全溶解；
(6)将步骤(5)中溶液缓慢滴加到步骤(4)的溶液中，并继续搅拌15min；
(7)2.34g单宁酸加入到40.0mL水中，超声至完全溶解；
(8)将步骤(7)中溶液缓慢滴加到步骤(6)的溶液中，室温搅拌16h；
(9)将步骤(8)中溶液离心，并用水和乙醇清洗，60℃干燥4h，然后置于400℃下煅烧3h，即得TCN；
(10)向离心管中加入7.5wt％150mg丙烯酸酯修饰的明胶；
(11)向步骤(10)的离心管中加入3.0mL水并超声至完全溶解；
(12)向离心管中加入15.0mg TCN、及2μL的浓度10wt％安息香二甲醚乙醇溶液，并超声至均匀；
(13)将步骤(12)的离心管置于紫外光下照射15min，安息香二甲醚作为光引发剂，丙烯酸酯修饰的明胶浓度较低，因此发生轻微交联，形成凝胶状水溶液，TCN均匀分散在凝胶水溶液中；
(14)向步骤(13)的离心管中加入过氧化氢溶液并在室温下超声至均匀即得TCNH滴眼液。
抑菌实验
将所得实施例制备的TCNH滴眼液应用于体外大肠杆菌、铜绿假单胞菌、耐药性铜绿假单胞菌和白色念珠菌评价以及体内铜绿假单胞菌和耐药铜绿假单胞菌角膜感染的预防治疗实验。
图4-图6为TCNH滴眼液的体外抑菌实验结果。铜绿假单胞菌、耐药铜绿假单胞菌、大肠杆菌和白色念珠菌的抑菌效果：如图4所示，对照组和H2O2组细菌长满了平板，TCNH和 TCNH+H2O2组平板无细菌菌落生成。如图5所示，对照组和H2O2组被染成绿色的活细菌数目较多，被染成红色的死细菌很少，TCNH和TCNH+H2O2组细菌个数显著减少，视野里只有零星几个。如图6所示，扫描电镜下对照组和H2O2组细菌形态规则完好，TCNH和TCNH+H2O2组细菌形貌变得不规则，有明显皱缩甚至凹陷。
TCNH滴眼液的体内抑菌实验(铜绿假单胞菌)，结果如图7所示，对照组和H2O2组角膜明显感染，TCNH组有轻微感染，TCNH+H2O2组无感染，角膜中细菌数量统计表明TCNH组细菌数量级显著降低。
TCNH滴眼液的体内抑菌实验(铜绿假单胞菌耐药菌)，结果如图8所示，对照组、庆大霉素组(Gen)和妥布霉素组(Tob)均有明显感染，TCNH+H2O2组无感染，角膜中细菌数量统计表明，TCNH组耐药细菌数量级显著降低。
以上所述的实施例仅是对本发明的优选实施方式进行描述，并非对本发明的范围进行限定，在不脱离本发明设计精神的前提下，本领域普通技术人员对本发明的技术方案作出的各种变形和改进，均应落入本发明权利要求书确定的保护范围内。

Claims (10)

  1. 纳米酶复合水凝胶滴眼液的制备方法，其特征在于，包括以下步骤：
    (1)向氯化钴水溶液中滴加少量氨水，反应一段时间，再滴加氯化钴水溶液继续反应；
    (2)将醋酸银加入到氨水溶液中并完全溶解，将该溶液缓慢滴加到步骤(1)中，搅拌一段时间后滴加单宁酸溶液，继续搅拌，析出沉淀；离心、清洗、干燥沉淀并于350-450℃下煅烧1-4h，即得单宁酸配合的银钴复合纳米粒子；
    (3)将制得的单宁酸配合的银钴复合纳米粒子加入到5wt％-7.5wt％的丙烯酸酯修饰明胶的水溶液中，并加入安息香二甲醚乙醇溶液作为引发剂，超声至均匀，然后将上述混合物置于紫外光下照射，形成凝胶状水溶液，再加入过氧化氢溶液并在室温下超声至均匀，即得纳米酶复合水凝胶滴眼液。
  2. 根据权利要求1所述的制备方法，其特征在于，所述氯化钴水溶液的浓度为20-30mmol/L。
  3. 根据权利要求1所述的制备方法，其特征在于，所述氨水为含氨20～28％的水溶液。
  4. 根据权利要求1所述的制备方法，其特征在于，所述步骤(1)向氯化钴水溶液中滴加氨水，逐步升温至55-65℃，并继续搅拌12-18min；再滴加氯化钴水溶液继续反应1-4h。
  5. 根据权利要求1所述的制备方法，其特征在于，所述步骤(2)缓慢滴加银氨溶液，搅拌15min，缓慢滴加单宁酸溶液，室温搅拌16h。
  6. 根据权利要求1所述的制备方法，其特征在于，所述步骤(2)依次用水和乙醇清洗，60℃干燥4h，然后置于400℃下煅烧3h。
  7. 根据权利要求1所述的制备方法，其特征在于，所述丙烯酸酯修饰明胶为甲基丙烯酸酯化明胶。
  8. 根据权利要求1所述的制备方法，其特征在于，所述步骤(3)混合物中，丙烯酸酯修饰明胶的质量浓度为2.0％-6.0％。
  9. 根据权利要求1所述的制备方法，其特征在于，所述步骤(3)紫外光下照射时间为12-18min。
  10. 根据权利要求1或2所述的制备方法，其特征在于：所述步骤(3)混合物中，丙烯酸酯修饰明胶与单宁酸配合的银钴复合纳米粒子的质量比为(8-12)：1。
PCT/CN2023/076110 2022-08-11 2023-02-15 纳米酶复合水凝胶滴眼液的制备方法 WO2024031949A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210964063.3A CN115300459B (zh) 2022-08-11 2022-08-11 纳米酶复合水凝胶滴眼液的制备方法
CN202210964063.3 2022-08-11

Publications (1)

Publication Number Publication Date
WO2024031949A1 true WO2024031949A1 (zh) 2024-02-15

Family

ID=83862902

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/076110 WO2024031949A1 (zh) 2022-08-11 2023-02-15 纳米酶复合水凝胶滴眼液的制备方法

Country Status (2)

Country Link
CN (1) CN115300459B (zh)
WO (1) WO2024031949A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115300459B (zh) * 2022-08-11 2023-07-18 山东第一医科大学附属眼科研究所(山东省眼科研究所山东第一医科大学附属青岛眼科医院) 纳米酶复合水凝胶滴眼液的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000204182A (ja) * 1999-08-16 2000-07-25 Natl Inst Of Sericultural & Entomological Science 抗菌性高分子素材及びその製造方法
US20100251856A1 (en) * 2009-04-03 2010-10-07 Venugopal Santhanam Methods for preparing metal and metal oxide nanoparticles
CN114129766A (zh) * 2021-12-13 2022-03-04 昆明理工大学 一种纳米酶抗菌水凝胶的制备方法及其应用
CN115300459A (zh) * 2022-08-11 2022-11-08 山东第一医科大学附属眼科研究所(山东省眼科研究所 山东第一医科大学附属青岛眼科医院) 纳米酶复合水凝胶滴眼液的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXNL06000107A (es) * 2006-12-20 2008-10-08 Ind Penoles Sa De Cv Proceso para la fabricacion de plata metalica nanometrica, monodispersa y estable y producto obtenido.
US20130177504A1 (en) * 2011-06-17 2013-07-11 Annuary Healthcare, Inc. Nanoscale Particle Formulations and Methods
CN111363072A (zh) * 2020-03-06 2020-07-03 西南交通大学 一种基于具有等离子效应的多酚-银纳米酶的水凝胶制备方法
CN113248730A (zh) * 2021-04-22 2021-08-13 上海健康医学院 聚丙烯酰胺-纳米纤维素晶-银纳米颗粒复合导电抗冻有机水凝胶及其制备方法和应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000204182A (ja) * 1999-08-16 2000-07-25 Natl Inst Of Sericultural & Entomological Science 抗菌性高分子素材及びその製造方法
US20100251856A1 (en) * 2009-04-03 2010-10-07 Venugopal Santhanam Methods for preparing metal and metal oxide nanoparticles
CN114129766A (zh) * 2021-12-13 2022-03-04 昆明理工大学 一种纳米酶抗菌水凝胶的制备方法及其应用
CN115300459A (zh) * 2022-08-11 2022-11-08 山东第一医科大学附属眼科研究所(山东省眼科研究所 山东第一医科大学附属青岛眼科医院) 纳米酶复合水凝胶滴眼液的制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHANG GUO-CHAO; GAO QI; WEI XIAO-LE; HE QI; JIANG YU; MA XING-MING; YUAN MIAO-MIAO: "Preparation of cobalt-silver nanoparticles and preliminary study on its antibacterial activity", E-JOURNAL OF TRANSLATION MEDICINE, vol. 4, no. 11, 30 November 2017 (2017-11-30), pages 39 - 41, XP009553986, ISSN: 2095-6894 *

Also Published As

Publication number Publication date
CN115300459A (zh) 2022-11-08
CN115300459B (zh) 2023-07-18

Similar Documents

Publication Publication Date Title
Luo et al. Dual-functional gelatin-capped silver nanoparticles for antibacterial and antiangiogenic treatment of bacterial keratitis
AU2005251570B2 (en) Anti-microbial activity of biologically stabilized silver nano particles
JP6775523B2 (ja) オキソ水酸化銅ナノ粒子を含む抗細菌組成物およびそれらの殺生物剤としての使用
WO2024031949A1 (zh) 纳米酶复合水凝胶滴眼液的制备方法
US20210393680A1 (en) Use of an antimicrobial composition
EP3735218B1 (en) Coordination complexes having microbial activity and incorporable in hyaluronic acid compositions
JP5337928B2 (ja) 銀／水、銀ゲル、および銀ベースの組成物、並びにこれらの製造方法および使用方法
CN105999366A (zh) 一种显色医用敷料的制备方法
Sadek et al. Evaluation of the efficacy of three antimicrobial agents used for regenerative endodontics: an in vitro study
Guo et al. Reversible antibiotic loading and pH-responsive release from polymer brushes on contact lenses for therapy and prevention of corneal infections
Chen et al. Preparation, property of the complex of carboxymethyl chitosan grafted copolymer with iodine and application of it in cervical antibacterial biomembrane
TW201811180A (zh) 碳化多胺粒子及其用途
Yunusov et al. Physicochemical properties and antimicrobial activity of nanocomposite films based on carboxymethylcellulose and silver nanoparticles
JP5902672B2 (ja) コンタクトレンズおよび医療材料を維持するための液体形態の組成物
CN113041348B (zh) 具有一氧化氮/光动力协同抗菌、抗炎作用的纳米复合体系及其制备方法与应用
Nairy et al. A pseudo-randomised clinical trial of in situ gels of fluconazole for the treatment of oropharngeal candidiasis
Zhou et al. Antibiotics-free nanomaterials against bacterial keratitis: Eliminating infections with reactive oxygen species (ROS)
Maiti et al. Preparation of carboxy-methyl cellulose-capped nanosilver particles and their antimicrobial evaluation by an automated device
CN1369206A (zh) 钠米银消毒凝胶及其制备方法和应用
CN115304053B (zh) 碳纳米点、可注射碳纳米点-ε-聚赖氨酸水凝胶及其制备方法与应用
RU2146136C1 (ru) Антисептическое средство "катацел"
Marín-Correa et al. Nanosilver gel as an endodontic alternative against Enterococcus faecalis in an in vitro root canal system in Mexican dental specimens
WO2008157643A1 (en) Antimicrobial compositions
Mardones et al. In vitro antibacterial properties of copper nanoparticles as endodontic medicament against Enterococcus faecalis
CN107281095A (zh) 一种妇科用抗菌养护凝胶

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23851185

Country of ref document: EP

Kind code of ref document: A1